The groundbreaking success of Sildenafil undeniably reshaped the pharmaceutical landscape, but betting in companies strongly reliant on generic versions presents a complex picture. Although early profits were substantial, the cessation of patents and the appearance of discounted alternatives have diminished the customer base. Consequently, a thorou